These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 33987273)

  • 1. Cost-utility analysis of imrecoxib compared with celecoxib for patients with osteoarthritis.
    Sun X; Zhen X; Hu X; Li Y; Gu S; Gu Y; Zhao Z; Yang W; Dong H
    Ann Transl Med; 2021 Apr; 9(7):575. PubMed ID: 33987273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-utility analysis of imrecoxib compared with diclofenac for patients with osteoarthritis.
    Sun X; Zhen X; Hu X; Li Y; Gu S; Gu Y; Zhao Z; Yang W; Dong H
    Cost Eff Resour Alloc; 2021 Apr; 19(1):22. PubMed ID: 33879168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Cost-effectiveness of Celecoxib versus Non-steroidal Anti-inflammatory Drugs plus Proton-pump Inhibitors for Treating Osteoarthritis in Algeria.
    Hammoumraoui N; Kherraf SA; Mould-Quevedo J; Ismail TA
    J Health Econ Outcomes Res; 2013; 1(2):184-199. PubMed ID: 37662022
    [No Abstract]   [Full Text] [Related]  

  • 4. Postoperative analgesic efficacy and safety of imrecoxib versus celecoxib in hip osteoarthritis patients undergoing total hip arthroplasty: a multi-center, randomized, controlled, non-inferiority study.
    Zhang K; Miao X; Jiang L; Cui S; Liu Z; Wang Z
    Inflammopharmacology; 2023 Aug; 31(4):1813-1822. PubMed ID: 37306938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
    Chen YF; Jobanputra P; Barton P; Bryan S; Fry-Smith A; Harris G; Taylor RS
    Health Technol Assess; 2008 Apr; 12(11):1-278, iii. PubMed ID: 18405470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-utility analysis of duloxetine in osteoarthritis: a US private payer perspective.
    Wielage RC; Bansal M; Andrews JS; Klein RW; Happich M
    Appl Health Econ Health Policy; 2013 Jun; 11(3):219-36. PubMed ID: 23616247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cost-effectiveness analysis of celecoxib compared with diclofenac in the treatment of pain in osteoarthritis (OA) within the Swedish health system using an adaptation of the NICE OA model.
    Brereton N; Pennington B; Ekelund M; Akehurst R
    J Med Econ; 2014 Sep; 17(9):677-84. PubMed ID: 24914585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost-effectiveness of celecoxib versus non-steroidal anti-inflammatory drugs plus proton-pump inhibitors in the treatment of osteoarthritis in Saudi Arabia.
    Nasef SA; Shaaban AA; Mould-Quevedo J; Ismail TA
    Health Econ Rev; 2015 Dec; 5(1):53. PubMed ID: 26061682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Real-World Study on the Effect of Imrecoxib for Patients with Axial Spondyloarthritis.
    Zong HX; Xu SQ; Wang JX; Chu YR; Chen KM; Wang C; Tong WQ; Wang XL
    Drug Des Devel Ther; 2022; 16():2755-2765. PubMed ID: 36033132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An economic model of long-term use of celecoxib in patients with osteoarthritis.
    Loyd M; Rublee D; Jacobs P
    BMC Gastroenterol; 2007 Jul; 7():25. PubMed ID: 17610716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cost-effectiveness of celecoxib vs diclofenac in the treatment of osteoarthritis in the UK; an update to the NICE model using data from the CONDOR trial.
    Brereton N; Winn B; Akehurst R
    J Med Econ; 2012; 15(3):465-72. PubMed ID: 22260652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imrecoxib versus celecoxib as postoperative analgesia for patients receiving arthroscopic knee surgery: a randomized, controlled, non-inferiority study.
    Guo W; Liu Y; Li J
    Inflammopharmacology; 2022 Jun; 30(3):875-881. PubMed ID: 35445990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost effectiveness of duloxetine for osteoarthritis: a Quebec societal perspective.
    Wielage RC; Patel AJ; Bansal M; Lee S; Klein RW; Happich M
    Arthritis Care Res (Hoboken); 2014 May; 66(5):702-8. PubMed ID: 24877251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analgesic efficacy of imrecoxib for postoperative pain following oral surgery: a prospective randomized, active-controlled, non-inferiority trial.
    Jiang Y; Qi L; Liu J; Wu H; Li Y; Zou L; Guo Z; Wang J; Li H
    Ann Transl Med; 2021 Mar; 9(6):469. PubMed ID: 33850866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-utility analysis and economic burden of knee osteoarthritis treatment: the analysis from the real clinical practice.
    Turajane T; Chaweevanakorn U; Sungkhun P; Larbphiboonpong V; Wongbunnak R
    J Med Assoc Thai; 2012 Oct; 95 Suppl 10():S98-104. PubMed ID: 23451446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cost-effectiveness analysis of celecoxib versus non-selective non-steroidal anti-inflammatory drug therapy for the treatment of osteoarthritis in Spain: A current perspective].
    De Lossada A; Oteo-Álvaro Á; Giménez S; Oyagüez I; Rejas J
    Semergen; 2016; 42(4):235-43. PubMed ID: 26006311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-utility of celecoxib use in different treatment strategies for osteoarthritis and rheumatoid arthritis from the Quebec healthcare system perspective.
    Bessette L; Risebrough N; Mittmann N; Roussy JP; Ho J; Zlateva G
    J Med Econ; 2009 Sep; 12(3):246-58. PubMed ID: 19743942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imrecoxib and celecoxib affect sacroiliac joint inflammation in axSpA by regulating bone metabolism and angiogenesis.
    Guo Y; Jiang D; Mai Z; Chen Y; Li T; Gao G
    Clin Rheumatol; 2023 Jun; 42(6):1585-1592. PubMed ID: 36800138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Efficacy of Imrecoxib and Celecoxib in Axial Spondyloarthritis and Their Influence on Serum Dickopff-Related Protein 1 (DKK-1) Levels.
    Gao GM; Li YM; Zheng XL; Jiang DB; Zhang LL; Xu PH; Liu SY; Zheng ZH; Kan QC
    Med Sci Monit; 2017 Jun; 23():2985-2992. PubMed ID: 28626213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost Effectiveness of Durvalumab in Unresectable Stage III NSCLC: 4-Year Survival Update and Model Validation from a UK Healthcare Perspective.
    Dunlop W; van Keep M; Elroy P; Perez ID; Ouwens MJNM; Sarbajna T; Zhang Y; Greystoke A
    Pharmacoecon Open; 2022 Mar; 6(2):241-252. PubMed ID: 34532842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.